Authors
The U.S. Securities and Exchange Commission (SEC) has proposed rules that, if adopted, would require most U.S. reporting companies1 to report detailed climate-related information in certain SEC filings. Most of the proposed rules would not apply to Canadian companies that report under the multijurisdictional disclosure system (MJDS). The deadline for commenting on the SEC proposal has been extended to June 17, 2022.
The proposed SEC rules would apply to U.S. reporting companies, including SEC foreign issuers other than Canadian MJDS filers, and would require such issuers to include prescribed climate-related disclosures in specified registration statements for securities offerings (Forms F-1, S-1, F-3 and S-3) and M&A transactions (Forms F-4 and S-4), annual reports on Forms 10-K (for domestic U.S. reporting companies) and 20-F (for foreign non-MJDS issuers), and audited financial statements. In addition, domestic U.S. reporting companies would be required to disclose in their quarterly reports on Form 10-Q any material changes to their previous climate-related disclosure.
Although the SEC is not proposing to amend Form 40-F, the annual reporting form that Canadian MJDS issuers use, it has requested feedback on whether Form 40-F filers should be required to comply with the SEC’s proposed climate-related disclosure requirements.
If the SEC’s proposed rules are adopted, a Canadian issuer planning to go public in the U.S. that was not eligible to use the southbound MJDS system would be required to provide climate-related disclosures in its initial SEC registration statement and in its annual reports thereafter, unless and until it became MJDS-eligible. By contrast, an MJDS-eligible Canadian company completing a cross-listing in the U.S. would not have to comply with the SEC rules as currently proposed in connection with its initial SEC registration or thereafter (unless and until MJDS status was lost).
The SEC has not proposed any changes to Form 8-K, the form of current report for U.S. domestic reporting companies. It is proposing, however, to amend Form 6-K, which is the form of current report that foreign private issuers (including MJDS issuers) furnish to the SEC in lieu of Form 8-K. In Form 6-K, “climate-related disclosure” would be added as an item that might trigger a requirement to furnish a report on Form 6-K to the extent the information is material and the issuer:
Consistent with other disclosure requirements in Form 6-K, the proposed amendments to Form 6-K do not specify whether or when a foreign private issuer must report material climate-related information or what the content should be of such disclosure. Instead, the form and content of any such climate-related disclosure that would be attached to the Form 6-K generally would be determined by home country disclosure requirements.
Some Canadian public companies already disclose climate-related information pursuant to general securities law or stock exchange requirements to disclose material information or voluntarily, for example, in alignment with TCFD or general sustainability reporting frameworks. As Canadian climate-related disclosure requirements evolve, Canadian companies that are also U.S. reporting companies will need to consider, among other things, whether the climate-related information they are required to make public, file under stock exchange rules or distribute to their securityholders is material and should be furnished to the SEC on Form 6-K.
The SEC’s proposed rules may also have implications for M&A transactions. For example, the proposed rules require climate-related disclosures with respect to the company being acquired under certain circumstances and do not contemplate any transition period in respect of newly acquired companies. (However, the SEC has asked commentators if transitional relief should be provided in respect of recently acquired companies.)
The SEC is proposing to require U.S. reporting companies (other than Canadian MJDS issuers) to disclose in the notes to their annual financial statements certain disaggregated climate-related financial statement metrics and related disclosures. The disclosures would be required for the company’s most recently completed fiscal year and for the fiscal years included in the consolidated financial statements for the relevant filing. The scope of the proposed disclosures would encompass matters such as:
The SEC is also proposing to require companies to quantify any such impact if the positive or negative effect exceeded 1% for any financial statement line item in the relevant fiscal period. In addition, for each type of financial statement metric, the company would also have to disclose contextual information to enable the reader to understand how the company derived the metric, including a description of significant inputs and assumptions used, and, if applicable, policy decisions made by the registrant to calculate the specified metrics. Companies would also be required to provide a qualitative discussion of the impact of any severe weather events or transition activities on estimates and assumptions used in the financial statements.
As part of the financial statements, the climate-related metrics would be subject to audit by the company’s independent public accounting firm and come within the scope of the company’s internal controls over financial reporting.
The CSA has not proposed any climate-related financial statement disclosure requirements.
Like the CSA, the SEC is proposing to require U.S. reporting companies (other than Canadian MJDS issuers) to disclose how the board oversees climate-related risks, as well as management’s role in assessing and managing climate-related risks, both of which are key TCFD recommendations. Also like the CSA, the SEC is not proposing to set any materialitity threshold for such disclosures.
The SEC’s proposed rules specify in significantly more detail than the CSA’s proposed rules what companies must disclose regarding their governance structures and processes relating to climate-related risks. For example, the SEC is proposing to require disclosure, of among other things:
The SEC is proposing to require U.S. reporting companies (other than Canadian MJDS issuers) to describe climate-related risks (whether physical or transitional) that are reasonably likely to have a material impact over the short, medium and long term (Identified Climate Risks) and how any Identified Climate Risks have affected or are likely to affect the company’s strategy, financial planning, capital allocation, business model and outook. These proposed requirements are generally consistent with the CSA proposal.
The SEC is also proposing to require descriptions of companies’ processes for identifying, assessing and managing climate-related risks and whether any such processes are integrated into the registrant’s overall risk management system or processes (without regard to materiality). These requirements (including the lack of a materiality qualifier) are broadly similar to the CSA’s proposed requirements.
The SEC’s proposed rules specify in significantly more detail what must be disclosed about the nature, extent, severity and potential impacts of Identified Climate Risks and regarding their risk identification, assessment and management practices and strategies. For example, companies would be required to disclose:
Under the SEC proposal, companies would also be required to provide current and forward-looking disclosure of whether and how any Identified Climate Risks affected, or would be reasonably likely to affect, their consolidated financial statements, including the climate-related financial metrics described above and regarding the resilience of the company’s business strategy in light of potential future changes in climate-related risks.
The SEC is proposing to require U.S. reporting companies (other than Canadian MJDS issuers) to disclose:
These disclosures would be required for the current fiscal year in which the report was made. For historical financial years included in the report, such disclosures would be required only if “reasonably available”.
In addition, certain U.S. reporting companies (other than Canadian MJDS issuers) would be subject to independent third-party attestation requirements in respect of their emissions disclosure, depending on their filer status.
In respect of Scope 3 emissions disclosures, the SEC is proposing a safe harbour that would provide that disclosure of Scope 3 emissions by or on behalf of a company would be deemed not to be a fraudulent statement unless it was shown that the statement was made or reaffirmed without a reasonable basis or was disclosed other than in good faith.
The CSA proposed a comply-or-explain approach to Scope 1, 2 and 3 GHG emissions disclosure, while indicating that it was also considering mandatory reporting of Scope 1 emissions.
Unlike the SEC, the CSA did not propose any requirements relating to attestation reports.
The SEC is proposing to require U.S. reporting companies (other than Canadian MJDS issuers) that have publicly set climate-related targets or goals to disclose information about the scope, time horizon and strategy to meet such targets as well as performance against such targets. The proposal would also require disclosure of the use of carbon offsets and renewable energy credits to the extent they play a role in the company’s climate-related strategy. In addition, if a company used an internal carbon price, information about that price and how it is set would have to be disclosed.
The CSA’s approach to targets and metrics differs in several respects. For example, disclosure regarding the metrics that a company uses to assess climate-related risks and opportunities, the targets used by the company to manage such risks and opportunities and the company’s performance against such targets would be required only if the information was material. Second, the CSA’s proposed rules do not specifically address internal carbon prices, renewable energy credits or the use of carbon offsets.
The SEC rule proposal makes it clear that to the extent any climate-related disclosures constitute “forward-looking statements”, the safe harbours in the U.S. Private Securities Litigation Reform Act (PSLRA) would apply, if the other prescribed conditions for such safe harbours were met. For example, the PSLRA’s safe harbours are not available for initial public offerings or offerings by partnerships.
The SEC’s proposed climate-related disclosure requirements would be phased in over several years, with the compliance deadline depending on the company’s filer status and the specific disclosure requirement. For example, if the rules become effective before the end of 2022:
Similar to the SEC, the CSA is proposing to phase in its climate-related disclosure requirements. Assuming that the CSA’s rules are finalized before the end of 2022, non-venture issuers with a December 31 year-end would have to comply in their annual filings due in 2024 (in respect of fiscal 2023). Venture issuers would have a three-year transition phase. For example, venture issuers with a December 31 year end would need to comply in their annual filings due in 2026 (in respect of fiscal year 2025).
Le mois dernier, le Canada a publié sa première Stratégie industrielle de défense (la Stratégie), qui souligne l’engagement du Canada à développer une base industrielle de défense solide et à stimuler la croissance économique. Ces efforts pourraient aussi comprendre le renforcement de l’état de préparation à la biodéfense et aux contre-mesures médicales, ce qui pourrait constituer des débouchés pour le secteur canadien des sciences de la vie en raison de l’importance accordée aux capacités nationales en ce sens et de la nécessité d’atténuer les risques d’urgences sanitaires.
Comme indiqué dans les bulletins précédents, le quatrième pilier de la Stratégie est axé sur la « sécurisation des chaînes d’approvisionnement pour les intrants et les biens clés » par le renforcement de la production nationale et le stockage de ressources. L’accent est mis tout particulièrement sur les contre-mesures médicales, en précisant que nos « alliés ont établi un lien explicite entre l’état de préparation à la biodéfense et aux contre-mesures médicales et leur sécurité économique et nationale, en élaborant de nouvelles stratégies et de nouveaux mécanismes pour faire progresser ces travaux ». Les contre-mesures médicales désignent divers produits réglementés pouvant être utilisés pour protéger la population lors d’une situation d’urgence de grande ampleur, comme l’éclosion d’une maladie ou une attaque impliquant des armes chimiques, biologiques ou nucléaires. Il peut s’agir de vaccins, de médicaments thérapeutiques et produits biologiques, de dispositifs de tests diagnostiques, des équipements de protection individuelle ou industrielle, et d’autres dispositifs médicaux. Les contre-mesures médicales sont essentielles à la réduction et à l’atténuation des dommages lors d’une urgence de santé publique.
Pendant et après la pandémie de COVID-19, le Canada a mis en place plusieurs nouvelles voies réglementaires comme mécanismes d’accélération des approbations de produits médicaux, ce qui pourrait offrir au gouvernement des options pour déployer des contre-mesures médicales afin de faire face aux risques pour la santé publique. Au début de la pandémie, Santé Canada a émis diverses ordonnances provisoires pour permettre l’importation et la vente de médicaments et de dispositifs médicaux qui n’avaient pas eu l’approbation des voies réglementaires traditionnelles. Or, Santé Canada a plutôt fait confiance aux voies d’approbation réglementaire et de l’exemption de certaines exigences en homologation de produits des pays impliqués dans la transaction. Beaucoup de ces règles provisoires ont depuis été officiellement intégrées à la réglementation en vertu de la Loi sur les aliments et drogues et ont été appliquées bien après la COVID-19. Conformément au Règlement sur les aliments et drogues, Santé Canada tient à jour la Liste des maladies qui menacent la santé publique et utilisera une procédure d’autorisation modifiée pour les médicaments d’urgence de santé publique pouvant traiter les affections figurant sur la liste. De même, le Règlement sur les instruments médicaux a établi une liste d’instruments médicaux répondant à un besoin urgent de santé publique, ce qui permet à Santé Canada d’autoriser la commercialisation de ces instruments de manière accélérée. Ces outils réglementaires sont utilisés automatiquement quand une situation médicale présente un grand risque pour la santé publique au Canada et nécessite une action immédiate pour contrer ce risque.
La stratégie prévoit que le Canada adoptera une approche proactive en matière de planification en amont des crises sanitaires. Le gouvernement entend s’assurer que les produits médicaux sont déjà disponibles au Canada afin qu’ils puissent être distribués rapidement en cas d’urgence. D’autres modifications récentes au Règlement sur les aliments et drogues permettent de prépositionner au Canada tous les médicaments d’urgence en santé publique, ce qui signifie qu’ils peuvent être importés dans des installations d’entreposage canadiennes avant que leur mise sur le marché n’ait été autorisée. La Stratégie s’appuie sur ces fondements, en faisant référence à l’organisme existant Préparation aux crises sanitaires Canada (PCSC), un organisme opérationnel spécial au sein d’Innovation, Sciences et Développement économique Canada (ISDE), et à un nouveau Fonds des sciences de la vie, lesquels « collaborent avec des partenaires internationaux et de soutenir l’élaboration et la production de contre-mesures médicales ». PCSC supervise la Stratégie en matière de biofabrication et de sciences de la vie du Canada, qui vise à développer un secteur national des sciences de la vie fort et compétitif doté de capacités de biofabrication de pointe, en mettant l’accent sur la capacité à se préparer et à faire face aux futures priorités et crises sanitaires. Dans cette optique, il y aura des occasions pour les fabricants de nouer des collaborations de recherche et des accords commerciaux ou d’approvisionnement liés aux contre-mesures médicales financées par des programmes fédéraux.
Étroitement lié aux capacités nationales, le pilier III de la stratégie implique « Investissement ciblé pour renforcer un secteur canadien de la défense novateur », avec la promesse que le gouvernement fédéral « soutiendr[a] la recherche et le développement, protéger[a] la propriété intellectuelle, soutiendr[a] les petites et moyennes entreprises, investir[a] dans les compétences et la formation, et encourager[a] les exportations afin de créer un secteur de la défense agile et concurrentiel à l’échelle mondiale ». La nécessité de favoriser le développement de la propriété intellectuelle (PI) et la conservation des droits du Canada est mentionnée à plusieurs reprises dans la Stratégie. Par exemple, la Stratégie prévoit l’établissement de partenariats officiels avec l’industrie canadienne qui « [assureront] la propriété et le contrôle nationaux de la propriété intellectuelle (PI) et des capacités essentielles. » La Stratégie reconnaît l’immense talent des établissements canadiens et la précieuse recherche qui y est menée actuellement et qui est déjà financée par des subventions de recherche d’organismes tels que le Conseil de recherches en sciences naturelles et en génie et les Instituts de recherche en santé du Canada, et fait aussi référence à l’engagement de 1,6 milliard de dollars pour de nouveaux fonds de recherche dans le budget de 2025. Cette prise de conscience de la nécessité de promouvoir et de soutenir l’innovation au Canada laisse présager des possibilités de financement, notamment dans les domaines où le Canada accuse un retard en matière de production nationale et où des engagements d’investissement et de fabrication au Canada peuvent être pris.
Dans les prochains mois, nous prévoyons que le gouvernement du Canada publiera d’autres directives et des mesures de suivi. L’équipe de défense des conservateurs poursuivra sa couverture de perspectives sur la défense au Canada en publiant une analyse supplémentaire pour donner des précisions sur l’incidence de la Stratégie sur de multiples secteurs.